Imunon Inc. has announced a potential delisting from The Nasdaq Capital Market after failing to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The company was initially given until May 27, 2025, to regain compliance, but did not meet the criteria by the deadline. Consequently, Imunon received a delisting determination letter on May 28, 2025. The company plans to request a hearing to appeal the decision and intends to present a compliance plan, which may include a reverse stock split, to maintain its Nasdaq listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.